Opportunity Information: Apply for CDC RFA GH16 160102CONT16
Apply for CDC RFA GH16 160102CONT16
- The HHS-CDC in the health sector is offering a public funding opportunity titled "Strengthening sustainable public health capacity in the Eastern Mediterranean Region for polio eradication and routine immunization activities" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.318.
- This funding opportunity was created on Apr 06, 2016 and posted on Apr 06, 2016.
- Applicants must submit their applications by Jun 06, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Strengthening sustainable public health capacity in the Eastern Mediterranean Region for polio eradication and routine immunization activities" is a continuation funding announcement from the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention (HHS-CDC). It is issued under Funding Opportunity Number CDC RFA GH16-160102CONT16 and is positioned within the Health funding activity area (CFDA 93.318). The focus is on reinforcing long-term, sustainable public health capacity in the Eastern Mediterranean Region, specifically in ways that support the final push toward polio eradication while also improving routine immunization systems that prevent other vaccine-preventable diseases.
This opportunity is structured as a cooperative agreement, which generally indicates that CDC expects to have substantial involvement in program direction, technical assistance, and oversight during the period of performance rather than simply providing funds with minimal engagement. In practical terms, a cooperative agreement often supports work where CDC expertise, coordination, or close collaboration is important for achieving complex public health outcomes, such as maintaining high-quality surveillance, improving immunization delivery, strengthening laboratory and data systems, and ensuring readiness to detect and respond to outbreaks.
Because this is categorized as a continuation opportunity, it is typically intended to extend or build upon an existing project or previously funded work rather than start a brand-new initiative from scratch. Continuation announcements often aim to maintain momentum, preserve operational capacity, and support ongoing activities that have already been established under an earlier award. This aligns with the stated emphasis on "strengthening sustainable" capacity, meaning the funded work is expected to develop durable systems and workforce capability that can persist beyond short-term emergency efforts and remain useful for routine immunization and broader disease control needs.
The geographic emphasis is the Eastern Mediterranean Region, a WHO-defined region that includes multiple countries where polio eradication efforts have historically required intensive support due to challenges such as conflict, population movement, gaps in health service delivery, and uneven immunization coverage. Within that context, the opportunity title signals two closely linked objectives: (1) polio eradication activities, which commonly include acute flaccid paralysis surveillance, environmental surveillance in some settings, outbreak preparedness and response, supplemental immunization activities, microplanning, monitoring, and targeted strategies for hard-to-reach populations; and (2) routine immunization strengthening, which typically includes improving vaccine delivery systems, cold chain and logistics, immunization data quality, supervision and training, demand generation, and integration with primary health care services. The pairing of polio eradication with routine immunization suggests an intent to ensure that assets and capacities built for polio (such as trained staff, surveillance networks, data systems, and community engagement mechanisms) also reinforce wider immunization and public health functions rather than remaining siloed.
The eligibility field indicates "Others (see text field entitled Additional Information on Eligibility for clarification)," which implies that eligibility may be restricted or specifically defined in the full announcement text. In many CDC continuation notices, eligible applicants are limited to the current recipient(s) of the underlying award or a defined set of partners. Without the additional eligibility text, the safest interpretation is that eligibility is not broadly open to all organizations and would require checking the full funding opportunity documentation for the precise criteria.
Key administrative details include an original and current closing date of June 6, 2016, with a creation and posting date of April 6, 2016. The listing shows an award ceiling of 0 and no expected awards value provided, which often happens in continuation postings or in records where the funding amount is not displayed in the summary table. That does not necessarily mean there is no funding; it more commonly indicates that the funding level is determined by the existing award, availability of appropriations, or other internal CDC factors and is documented elsewhere in the full notice or in continuation award paperwork.
Overall, the opportunity is best understood as CDC support, delivered through a collaborative cooperative agreement mechanism, to sustain and deepen the operational and institutional capabilities needed to finish polio eradication objectives in the Eastern Mediterranean Region while simultaneously strengthening routine immunization performance. The underlying theme is sustainability: building public health systems, workforce skills, and program infrastructure that continue to deliver benefits beyond polio, including stronger surveillance, better immunization coverage, improved data use, and more resilient health service delivery in complex settings.
Frequently Asked Questions (FAQs)
What is the title of this grant opportunity?
The opportunity is titled "Strengthening sustainable public health capacity in the Eastern Mediterranean Region for polio eradication and routine immunization activities."
Which federal agency is offering this opportunity?
This is a continuation funding announcement from the U.S. Department of Health and Human Services (HHS), Centers for Disease Control and Prevention (CDC).
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is CDC RFA GH16-160102CONT16.
What is the CFDA number and funding activity area?
The opportunity is listed under CFDA 93.318 and is positioned within the Health funding activity area.
What type of funding mechanism is this?
This opportunity is structured as a cooperative agreement.
What does a cooperative agreement mean for how the project will be run?
A cooperative agreement generally indicates that CDC expects substantial involvement during the period of performance, such as program direction, technical assistance, coordination, and oversight, rather than providing funding with minimal engagement.
Is this a new grant or continuation funding?
This is a continuation opportunity, meaning it is typically intended to extend or build on previously funded work rather than start a brand-new initiative from scratch.
What is the main purpose of the opportunity?
The purpose is to reinforce long-term, sustainable public health capacity in the Eastern Mediterranean Region in ways that support the final push toward polio eradication while also improving routine immunization systems and preventing other vaccine-preventable diseases.
What region is the focus of the grant?
The geographic emphasis is the Eastern Mediterranean Region, a WHO-defined region that includes multiple countries.
Why is the Eastern Mediterranean Region emphasized?
The opportunity notes that polio eradication efforts in the region have historically required intensive support due to challenges such as conflict, population movement, gaps in health service delivery, and uneven immunization coverage.
What kinds of polio eradication activities are referenced in the description?
Examples mentioned include acute flaccid paralysis (AFP) surveillance, environmental surveillance in some settings, outbreak preparedness and response, supplemental immunization activities, microplanning, monitoring, and targeted strategies for hard-to-reach populations.
What kinds of routine immunization strengthening activities are referenced?
Examples mentioned include improving vaccine delivery systems, cold chain and logistics, immunization data quality, supervision and training, demand generation, and integration with primary health care services.
How are polio eradication and routine immunization connected in this opportunity?
The description signals an intent to ensure that assets and capacities built for polio (such as trained staff, surveillance networks, data systems, and community engagement mechanisms) also strengthen broader immunization and public health functions rather than remaining siloed.
What does "strengthening sustainable public health capacity" imply?
It implies developing durable systems and workforce capability that can persist beyond short-term emergency efforts and remain useful for routine immunization and broader disease control needs.
What kinds of public health capacities does the opportunity suggest CDC may support?
The description points to complex public health outcomes such as maintaining high-quality surveillance, improving immunization delivery, strengthening laboratory and data systems, and ensuring readiness to detect and respond to outbreaks.
Who is eligible to apply?
The eligibility field is listed as "Others (see text field entitled Additional Information on Eligibility for clarification)," which implies eligibility may be restricted or specifically defined in the full announcement text.
Is eligibility broadly open to all organizations?
Based on the information provided, the safest interpretation is that eligibility is not clearly broad and may be limited (often, in CDC continuation notices, to current recipient(s) of the underlying award or a defined set of partners). The precise criteria would need to be confirmed in the full funding opportunity documentation.
What are the key dates shown for this opportunity?
The creation and posting date is April 6, 2016. The original closing date and current closing date are both June 6, 2016.
What is the award ceiling and expected award amount?
The listing shows an award ceiling of 0 and does not provide an expected awards value in the summary table.
Does an award ceiling of 0 mean there is no funding available?
Not necessarily. The description notes that in continuation postings or some summary records, funding amounts may not be displayed and may instead be determined by the existing award, availability of appropriations, or internal CDC factors documented elsewhere.
What is the overall theme or strategic emphasis of the opportunity?
The underlying theme is sustainability: sustaining and deepening operational and institutional capabilities needed to finish polio eradication objectives while also improving routine immunization performance and broader health system resilience.
What outcomes is this opportunity ultimately trying to support?
Based on the description, it aims to support progress toward polio eradication and to strengthen routine immunization and public health systems, including stronger surveillance, better immunization coverage, improved data use, and more resilient health service delivery in complex settings.
Browse more opportunities from the same category: Health
Next opportunity: Youth Engagement, Education, and Employment Programs
Previous opportunity: PM/WRA Burma HMA Request for Information (RFI)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA GH16 160102CONT16
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA GH16 160102CONT16) also looked into and applied for these:
| Funding Opportunity |
|---|
| Building Public Health Capacity for Drought Response Apply for CDC RFA EH16 1603 Funding Number: CDC RFA EH16 1603 Agency: HHS-CDC-NCEH Category: Health Funding Amount: $150,000 |
| NEI Research Grant for Vision Related Secondary Data Analysis (R21) Apply for PAR 16 168 Funding Number: PAR 16 168 Agency: HHS-NIH11 Category: Health Funding Amount: $200,000 |
| Educating State-level Stakeholders on Strategies to Address Winnable Battles in Public Health Apply for CDC RFA SO15 150102CONT16 Funding Number: CDC RFA SO15 150102CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Identification of Small Molecules for Sustained-Release Anti-HIV Products (R01) Apply for RFA AI 16 024 Funding Number: RFA AI 16 024 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Advancing HIV Therapeutic Vaccine Science (U01) Apply for RFA AI 16 019 Funding Number: RFA AI 16 019 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Human Tissue Models for Infectious Diseases (U19) Apply for RFA AI 16 022 Funding Number: RFA AI 16 022 Agency: HHS-NIH11 Category: Health Funding Amount: $1,000,000 |
| Noise-Induced Cochlear Synaptopathy: Basic Studies Informing Potential Therapies (R01) Apply for PAR 16 170 Funding Number: PAR 16 170 Agency: HHS-NIH11 Category: Health Funding Amount: $500,000 |
| Innovation for HIV Vaccine Discovery (R01) Apply for PAR 16 171 Funding Number: PAR 16 171 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Limited Competition: IDeA (Institutional Development Award) Core Optimization (Admin Supp) Apply for PA 16 172 Funding Number: PA 16 172 Agency: HHS-NIH11 Category: Health Funding Amount: $350,000 |
| Research Partnerships for Scaling Up Mental Health Interventions in Low-and Middle-Income Countries (U19) Apply for PAR 16 174 Funding Number: PAR 16 174 Agency: HHS-NIH11 Category: Health Funding Amount: $500,000 |
| Affordable Care Act Program for Early Detection of Certain Medical Conditions Related to Environmental Health Hazards Apply for CDC RFA TS15 150102CONT16 Funding Number: CDC RFA TS15 150102CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Resiliency in Communities After Stress and Trauma (Short Title: ReCAST Program) Apply for SM 16 012 Funding Number: SM 16 012 Agency: HHS-SAMHS Category: Health Funding Amount: $1,000,000 |
| ResPECT Data Anaysis Apply for EP IDS 16 002 Funding Number: EP IDS 16 002 Agency: HHS-OS-ASPR Category: Health Funding Amount: $386,500 |
| Limited Competition: Tissue Chips for Rare Diseases (Admin Supp) Apply for PA 16 173 Funding Number: PA 16 173 Agency: HHS-NIH11 Category: Health Funding Amount: $100,000 |
| Limited Competition: Tissue Chips and Missing Organs (Admin Supp) Apply for PA 16 178 Funding Number: PA 16 178 Agency: HHS-NIH11 Category: Health Funding Amount: $50,000 |
| Minority AIDS Initiative Continuum of Care Pilot (MAI-CoC) Syringe Services Programs (SSPs) (Short Title: MAI-CoC: SSP) Apply for SP 16 008 Funding Number: SP 16 008 Agency: HHS-SAMHS Category: Health Funding Amount: $82,500 |
| TRANSFORM/WASH Apply for RFA 663 16 000007 Funding Number: RFA 663 16 000007 Agency: USAID-ETH Category: Health Funding Amount: $24,000,000 |
| Tribal Management Grant Program Apply for HHS 2016 IHS TMD 0001 Funding Number: HHS 2016 IHS TMD 0001 Agency: HHS-IHS Category: Health Funding Amount: $100,000 |
| Development and Commercialization of Technologies to Create, Characterize or Improve Animal Models of Human Disease (R41/R42) Apply for PA 16 181 Funding Number: PA 16 181 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Development and Commercialization of Technologies to Create, Characterize or Improve Animal Models of Human Disease (R43/R44) Apply for PA 16 180 Funding Number: PA 16 180 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA GH16 160102CONT16", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.